Silencing of RAD51C expression has also been shown to make tumor cells more sensitive to PARPi in vitro and has also been replicated in clinical trials for patients with ovarian cancer who had an increased response rate to rucaparib [101,103]. Here, RAD51C is linked to ovarian cancer.